The company is developing a new respiratory diagnostic test for children.
The post Rhinomed (ASX:RNO) share price surges 9% on world-first trial result appeared first on The Motley Fool Australia. –
At the time of writing, shares in the company are trading at 29 cents, up 9.43%.
Let’s take a closer look at the news from the diagnostic company today.
What did the company announce?
Rhinomed announced results from a “world first” clinical trial of a diagnostic test for respiratory viruses in children. This includes the ability to detect coronavirus, influenza, and pneumonia.
The clinical trial assessed the use of its patented Rhinoswab Junior to test children at the Murdoch Children’s Research Institute.
The test is designed to cause less discomfort for children compared to standard throat and deep nasal swabs.
The trial recruited 254 children aged between 4 and 18 years showing respiratory symptoms.
It found 82% of children would rather have the Rhinoswab Junior test than the standard combined throat and nose swab.
Meanwhile, 79% of parents and 82% of nurses preferred the children to be tested with Rhinoswab Junior.
The company said these trial results have been presented to local and international “key opinion leaders” and will be reported in a medical journal early in 2022.
Commenting on the clinical trial results, Rhinomed CEO Michael Johnson said:
The results of this world first study come at a vitally important time. Testing of children has always been problematic with high testing reluctance due in no small part to the fear and anxiety families have toward the testing process.
As we continue to deal with SARS-CoV-2 and its variants it is critically important that we enable mass, high frequency testing of children. The results of this trial and the previously published results from NSW Health Pathology provide clear evidence that we can easily and quickly test kids.
Rhinomed share price snapshot
The Rhinomed share price has soared by nearly 66% in the past 12 months and 21% in the past month alone.
The company has a market capitalisation of around $75 million based on its current share price.
The post Rhinomed (ASX:RNO) share price surges 9% on world-first trial result appeared first on The Motley Fool Australia.
Should you invest $1,000 in Rhinomed right now?
Before you consider Rhinomed , you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Rhinomed wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
Motley Fool contributor Monica O’Shea has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.